Zhou Xinyi, Jin Nan, Chen Baoan
Department of Hematology and Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu 210009, P.R. China.
Oncol Lett. 2021 Apr;21(4):318. doi: 10.3892/ol.2021.12579. Epub 2021 Feb 23.
Cytomegalovirus (CMV) is an opportunistic virus, whereby recipients are most susceptible following allogeneic hematopoietic stem cell transplantation (allo-HSCT). With the development of novel immunosuppressive agents and antiviral drugs, accompanied with the widespread application of prophylaxis and preemptive treatment, significant developments have been made in transplant recipients with human (H)CMV infection. However, HCMV remains an important cause of short- and long-term morbidity and mortality in transplant recipients. The present review summarizes the molecular mechanism and risk factors of HCMV reactivation following allo-HSCT, the diagnosis of CMV infection following allo-HSCT, prophylaxis and treatment of HCMV infection, and future perspectives. All relevant literature were retrieved from PubMed and have been reviewed.
巨细胞病毒（CMV）是一种机会性病毒，在异基因造血干细胞移植（allo-HSCT）后，受者最易感染。随着新型免疫抑制剂和抗病毒药物的发展，以及预防和抢先治疗的广泛应用，移植受者的人（H）CMV感染取得了显著进展。然而，HCMV仍然是移植受者短期和长期发病及死亡的重要原因。本综述总结了allo-HSCT后HCMV再激活的分子机制和危险因素、allo-HSCT后CMV感染的诊断、HCMV感染的预防和治疗以及未来展望。所有相关文献均从PubMed检索并进行了综述。
